SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-24-002765
Filing Date
2024-05-10
Accepted
2024-05-10 16:07:16
Documents
15
Period of Report
2024-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_051024.htm   iXBRL 8-K 22311
2 EXHIBIT 99.1 exh_991.htm EX-99.1 49552
  Complete submission text file 0001171843-24-002765.txt   296961

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE sava-20240510.xsd EX-101.SCH 3762
4 XBRL DEFINITION FILE sava-20240510_def.xml EX-101.DEF 26604
5 XBRL LABEL FILE sava-20240510_lab.xml EX-101.LAB 36649
6 XBRL PRESENTATION FILE sava-20240510_pre.xml EX-101.PRE 25228
18 EXTRACTED XBRL INSTANCE DOCUMENT f8k_051024_htm.xml XML 5601
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 24934873
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)